1. Scrip

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

 
• By Joseph Haas

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.

FDA Approved typed words on a vintage typewriter
BioCryst gets FDA approval of first oral prophylaxis for HAE

With the market for prophylaxis of hereditary angioedema dominated by injectable therapies, BioCryst Pharmaceuticals, Inc. believes it is poised to capture significant market share with the first US approval of an oral agent, kallikrein inhibitor Orladeyo (berotralstat) – and to make sure of that it is undercutting the price of the segment leader, Takeda Pharmaceutical Co. Ltd.’s Takhzyro.

BioCryst’s Orladeyo obtained US Food and Drug Administration approval on 3 December, with approval in Japan expected before the end of 2020 and an EU thumbs-up anticipated during the second...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.